New Humapen
®
Savvio
™
Eli Lilly (S.A.) (Pty) Ltd. Reg. No. 1957/000371/07
1 Petunia Road, Bryanston, 2021. (011) 510-9300
ZADBT00299 Feb 2014
1923
- Launched Iletin
1982
- Launched Humulin
®
1990
- Launched Humalog
®
Now Who’s Savvy
Full reimbursement on all Lilly
Insulin Cartridges
HumaPen
®
SAVVIO™ is a new medical device that
doesn’t look like one. This short, lightweight, reusable
insulin pen has a sleek, contemporary design and choice
of 6 vibrant colours.
People are unique. Their pens should be, too.
www. lillydiabetes.co.za
0HDOWLPH LQVXOLQ KDV VLPSOLßHG P\
HYHU\GD\ OLIH DOORZLQJ PH WR IRFXV RQ
P\ KHDOWK
FRQWUROOLQJ P\ GLDEHWHV
Killian Webb 1760
References:
1.
Bowering K, Reed VA, Felicio J,
et al
. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 dia-
betes who have inadequate glycaemic control on oral antihyperglycaemic medication: results of the PARADIGM study.
Diab Med
2012; 29; e263-e272.
2.
MaloneJK
etal.
L isproMixture-GlargineStudyGroup.Combined therapywith insulin lisproMix75/25plusmetforminor insulinglargineplusmetformin:
a 16 week randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
Clin Ther
2004 Dec; 26(12): 2034-44.
3.
Malone JK
et al
. Twice-daily premixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2
diabetes.
Diabet Med
2005 Apr 22(4): 374-81.
4.
Niskanen L, Jensen LE, Råstam J,
et al
. Randomized, Multinational, Open-Label, 2-Period, Crossover
Comparison of Biphasic Insulin Aspart 30 and Biphasic Insulin Lispro 25 and Pen Devices in Adult Patients with Type 2 Diabetes Mellitus.
Clin Ther
,
2004; 26: 531-540. Product information: S3 Humalog
®
Mix25
™
Suspension for injection. Insulin lispro (rDNAorigin)25% Insulin lispro,75% Insulin lisproprotamine
suspension(NPL)100IU/ml.Reg.No.33/21.1/0073. ForfullprescribinginformationpleaserefertothepackageinsertcurrentlyapprovedbytheMedicineRegulatoryAuthority.
Human insulin solution for injection (rDNA origin)
Human insulin isophane suspension for injection (rDNA origin)
30% Human insulin regular injection (rDNA origin)
70% Human insulin isophane suspension for injection
•
Humalog Mix25 reduction in HbA1c results non-inferior to insulin
glargine plus Humalog
1
•
In insulin-naive patients, Humalog Mix25 demonstrated significantly
greater reduction in HbA1c compared to insulin glargine
2
•
In patients previously treated with insulin, Humalog Mix25 offered
significantly greater PPG control than insulin glargine
3
•
Humalog Mix25 reduction in HbA1c and PPG control results are
non-inferior to Biphasic Insulin Aspart 30
4
,WV P\ SHQ
0HDOWLPH LQVXOLQ KDV VLPSOLßHG P\
HYHU\GD\ OLIH DOORZLQJ PH WR IRFXV RQ
P\ KHDOWK
FRQWUROOLQJ P\ GLDEHWHV
